Dublin, May 30, 2023 (GLOBE NEWSWIRE) -- The "Global Antibiotics Partnering Terms and Agreements 2010 to 2023" report has been added to ResearchAndMarkets.com's offering.
The Global Antibiotics Partnering Terms and Agreements 2010 to 2023 report provides an understanding and access to the antibiotics partnering deals and agreements entered into by the worlds leading healthcare companies.
The report provides a detailed understanding and analysis of how and why companies enter antibiotics partnering deals. The majority of deals are early development stage whereby the licensee obtains a right or an option right to license the licensors antibiotics technology or product candidates. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.
Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not.
This report contains over 340 links to online copies of actual antibiotics deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal.
Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal.
The initial chapters of this report provide an orientation of antibiotics dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in antibiotics dealmaking since 2010, including details of average headline, upfront, milestone and royalty terms.
Chapter 3 provides a review of the leading antibiotics deals since 2010. Deals are listed by headline value, signed by big pharma, most active antibiotics dealmaking companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.
Chapter 4 provides a comprehensive listing of the top 25 most active companies in antibiotics dealmaking with a brief summary followed by a comprehensive listing of antibiotics deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.
Chapter 5 provides a comprehensive and detailed review of antibiotics partnering deals signed and announced since Jan 2010, where a contract document is available in the public domain. The chapter is organized by company A-Z, deal type (collaborative R&D, co-promotion, licensing etc), and specific therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
Chapter 6 provides a comprehensive and detailed review of antibiotics partnering deals signed and announced since Jan 2010. The chapter is organized by specific antibiotics technology type in focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
In addition, a comprehensive appendix is provided organized by antibiotics partnering company A-Z, deal type definitions and antibiotics partnering agreements example. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
Report scope
Global Antibiotics Partnering Terms and Agreements 2010 to 2023 includes:
- Trends in antibiotics dealmaking in the biopharma industry since 2010
- Analysis of antibiotics deal structure
- Access to headline, upfront, milestone and royalty data
- Access to over 340 antibiotics deal records and contract documents where available
- The leading antibody deals by value since 2010
- Most active antibiotics dealmakers since 2010
- The leading antibiotics partnering resources
This report provides details of the latest antibiotics agreements announced in the healthcare sectors, covering:
- Antibiotics
- Aminoglycosides
- Cephalosporin
- Clindamycin
- Macrolides
- Penicillin
- Quinolones
- Sulfonamides
- Tetracycline
In Global Antibiotics Partnering Terms and Agreements 2010 to 2023, the available contracts are listed by:
- Company A-Z
- Headline value
- Stage of development at signing
- Deal component type
- Specific therapy and technology target
Key Topics Covered:
Executive Summary
Chapter 1 - Introduction
Chapter 2 - Trends in antibiotics dealmaking
2.1. Introduction
2.2. Antibiotics partnering over the years
2.3. Most active antibiotics dealmakers
2.4. Antibiotics partnering by deal type
2.5. Antibiotics partnering by therapy area
2.6. Antibiotics partnering by industry sector
2.7. Deal terms for antibiotics partnering
2.7.1 Antibiotics partnering headline values
2.7.2 Antibiotics deal upfront payments
2.7.3 Antibiotics deal milestone payments
2.7.4 Antibiotics royalty rates
2.8. The anatomy of an antibiotics deal
Chapter 3 - Leading antibiotics deals
3.1. Introduction
3.2. Top antibiotics deals by value
Chapter 4 - Most active antibiotics dealmakers
4.1. Introduction
4.2. Most active antibiotics dealmakers
4.3. Most active antibiotics partnering company profiles
Chapter 5 - Antibiotics contracts dealmaking directory
5.1. Introduction
5.2. Antibiotics contracts dealmaking directory
Chapter 6 - Antibiotics dealmaking by technology type
Companies Mentioned
- Oxford Drug Design
- Gilead Sciences
- MD Anderson Cancer Center
- Biomedical Advanced Research and Development Authority
- Lysando
- Warp Drive Bio
- Centre for Drug Research and Development (CDRD)
- InSite Vision
- France's General Directorate for Armaments
- Q-linea AB
- Basilea Pharmaceutica
- European Commission
- European Union
- XBiotech
- QureTech Bio
- AnnaMed
- Dr. Reddy's Laboratories
- NovaMedica
- The Medicines Company
- The Regents of the University of California
- Paratek Pharmaceuticals
- Stiefel Laboratories
- Decibel Therapeutics
- NacuGen Therapeutics
- Quotient Bioresearch
- Emergent BioSolutions
- Novasep
- Polypeptide Laboratory
- Premier Inc
- Optimer Pharmaceuticals
- Auspherix
- Strides Arcolab
- Synthetic Biologics
- Medimetriks
- SINTEF
- Dana-Farber Cancer Institute
- Finorga
- Allergan
For more information about this report visit https://www.researchandmarkets.com/r/la24jp
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
